INFUSE® Bone Graft is recombinant human bone morphogenetic protein-2(rhBMP-2) applied to an absorbable collagen sponge carrier(ACS). One of the functions of the protein is to stimulate natural bone formation. Overall, bone morphogenetic protein technology has a lengthy history of extensive research and study dating back more than 50 years.
INFUSE® Bone Graft was approved by the U.S. Food & Drug Administration in 2002 for use in Anterior Lumbar Interbody Fusion spine surgical procedures. Additional approvals were received in 2004 and 2007 for trauma and oral-maxillofacial (OMF) indications, respectively.
In 2008, INFUSE® Bone Graft received the coveted Prix Galien Award. The distinguished award recognizes those scientific technologies that have revolutionized their field and significantly impacted the practice of science and medicine.